288 results on '"Goldstein, Steven C."'
Search Results
2. Eltrombopag for Treating Thrombocytopenia after Allogeneic Stem Cell Transplantation
3. α1-Antitrypsin infusion for treatment of steroid-resistant acute graft-versus-host disease
4. Increased bone marrow CD56bright natural killer cells at 30 days after allogeneic stem cell transplantation associated with adverse patient outcome
5. Impact of Next-Generation Sequencing Cell-free Pathogen DNA Test on Antimicrobial Management in Adults with Hematological Malignancies and Transplant Recipients with Suspected Infections
6. CCR Translation on this Article from A Phase I Study of Bexarotene, a Retinoic X Receptor Agonist, in Non-M3 Acute Myeloid Leukemia
7. Supplementary Methods and Table 1 from Phase I Study of Topotecan, Ifosfamide, and Etoposide (TIME) with Autologous Stem Cell Transplant in Refractory Cancer: Pharmacokinetic and Pharmacodynamic Correlates
8. Reducing Treatment-Related Mortality Did Not Improve Outcomes of Allogeneic Myeloablative Hematopoietic Cell Transplantation for High-Risk Multiple Myeloma: A University of Michigan Prospective Series
9. Single and Multiple Dose MultiStem (Multipotent Adult Progenitor Cell) Therapy Prophylaxis of Acute Graft-versus-Host Disease in Myeloablative Allogeneic Hematopoietic Cell Transplantation: A Phase 1 Trial
10. Phase 3 clinical trial of steroids/mycophenolate mofetil vs steroids/placebo as therapy for acute GVHD: BMT CTN 0802
11. NMR Metabolic and Physiological Markers of Therapeutic Response
12. Treatment of Acute Graft-vs-Host Disease
13. Cryopreservation of Allogeneic Stem Cell Products
14. Concepts and Controversies in the Use of Novel Preparative Regimens for Allogeneic Stem Cell Transplantation
15. Pilot Study of Prophylactic Ex Vivo Costimulated Donor Leukocyte Infusion After Reduced-Intensity Conditioned Allogeneic Stem Cell Transplantation
16. Acute toxicities of unrelated bone marrow versus peripheral blood stem cell donation: results of a prospective trial from the National Marrow Donor Program
17. Allogeneic transplantation with myeloablative FluBu4 conditioning improves survival compared to reduced intensity FluBu2 conditioning for acute myeloid leukemia in remission
18. Characteristics of CliniMACS® System CD34-Enriched T Cell-Depleted Grafts in a Multicenter Trial for Acute Myeloid Leukemia-Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Protocol 0303
19. Use of Novel ‘quarter Point’ Assay for Improving CD34 Yield and Reducing Collection Times for HPC, Apheresis
20. Time to unrelated donor leukocyte infusion is longer, but incidence of GVHD and overall survival are similar for recipients of unrelated DLI compared to matched sibling DLI
21. A Comparison of HLA-Identical Sibling Allogeneic versus Autologous Transplantation for Diffuse Large B Cell Lymphoma: A Report from the CIBMTR
22. Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network
23. Unrelated Donor Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma
24. Allogeneic Transplants in Follicular Lymphoma: Higher Risk of Disease Progression after Reduced-Intensity Compared to Myeloablative Conditioning
25. Comparison of Myeloablative Versus Reduced-Intensity Conditioning Regimens in Allogeneic Stem Cell Transplant Recipients with Acute Myelogenous Leukemia in Complete Remission: A Cohort Study
26. Impact of Cryopreservation of Donor Grafts on Outcomes of Allogeneic Hematopoietic Cell Transplant (HCT)
27. NMR Metabolic and Physiological Markers of Therapeutic Response
28. Cryopreservation of Allogeneic Stem Cell Products
29. Treatment of Acute Graft-vs-Host Disease
30. Concepts and Controversies in the Use of Novel Preparative Regimens for Allogeneic Stem Cell Transplantation
31. Blockade of Lymphocyte Chemotaxis in Visceral Graft-versus-Host Disease
32. Conditioning regimen intensity and low-dose azacitidine maintenance after allogeneic hematopoietic cell transplantation for acute myeloid leukemia
33. Role of Post-Allogeneic Hematopoietic Stem Cell Transplantation Low-Dose Azacitidine for Prevention of Relapse in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Retrospective Analysis
34. Ruxolitinib Is a Safe and Effective Therapeutic Option for Management of Chronic Gvhd - a Single Center Experience
35. Allogeneic immunotherapy to optimize the graft-versus-tumor effect: concepts and controversies
36. Detection of Lactate With a Hadamard Slice Selected, Selective Multiple Quantum Coherence, Chemical Shift Imaging Sequence (HDMD-SelMQC-CSI) on a Clinical MRI Scanner: Application to Tumors and Muscle Ischemia
37. Post-transplant outcomes of induction therapy for myeloma: thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell support
38. 275 - Use of Novel ‘quarter Point’ Assay for Improving CD34 Yield and Reducing Collection Times for HPC, Apheresis
39. Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case-control study
40. Aggressive Leukemic Non-Nodal Mantle Cell Lymphoma With P53 Gene Rearrangement/Mutation is Highly Responsive to Rituximab/Ibrutinib Combination Therapy
41. Increased bone marrow CD56bright natural killer cells at 30 days after allogeneic stem cell transplantation associated with adverse patient outcome
42. Addition of Cladribine: Improving Standard of Care in Newly Diagnosed Acute Myeloid Leukemia
43. Nephrotoxicity of High-Dose Ifosfamide/Carboplatin/Etoposide in Adults Undergoing Autologous Stem Cell Transplantation
44. 250 - Comparison of Myeloablative Versus Reduced-Intensity Conditioning Regimens in Allogeneic Stem Cell Transplant Recipients with Acute Myelogenous Leukemia in Complete Remission: A Cohort Study
45. Single and Multiple Dose MultiStem (Multipotent Adult Progenitor Cell) Therapy Prophylaxis of Acute Graft-versus-Host Disease in Myeloablative Allogeneic Hematopoietic Cell Transplantation: A Phase 1 Trial
46. Aggressive Leukemic Non-Nodal Mantle Cell Lymphoma with P53 Gene Rearrangement/Mutation is Highly Responsive to Rituximab/Ibrutinib Combination Therapy
47. Residual Leukemia in the Bone Marrow and/or Peripheral Blood on Day 7 of Blinatumomab Therapy Predicts Response in B-Cell Acute Lymphoblastic Leukemia
48. Use of Nitazoxanide, an Anti-Parasitic Drug, for Management of Norovirus Ileo-Colitis in an Allogeneic Stem Cell Transplant Patient
49. Post-Transplant Low-Dose Azacitidine Can Improve Overall Survival in AML/MDS Patients and is Associated with Decrease Risks of Severe Acute and Chronic Gvhd
50. Eltrombopag Treatment for Primary and Secondary Thrombocytopenia Post Allogeneic and Autologous Stem Cell Transplantation is Effective and Safe
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.